Syros Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 0/6
Syros Pharmaceuticals has a total shareholder equity of $-11.1M and total debt of $41.1M, which brings its debt-to-equity ratio to -369.3%. Its total assets and total liabilities are $85.0M and $96.1M respectively.
Key information
-369.3%
Debt to equity ratio
US$41.08m
Debt
| Interest coverage ratio | n/a |
| Cash | US$58.28m |
| Equity | -US$11.12m |
| Total liabilities | US$96.12m |
| Total assets | US$85.00m |
Recent financial health updates
Recent updates
Syros Pharmaceuticals: Entering A Decisive Era With An Expected 2024 Phase 3 Readout
Jul 02Syros Pharmaceuticals: Rising Despite Dilution, A Must Look
Jan 14Syros Pharmaceuticals: A Major Vote Of Confidence From Insiders
Sep 20Syros gets FDA orphan drug designation for pancreatic cancer treatment SY-5609
Sep 13Syros Pharmaceuticals Q2 2022 Earnings Preview
Aug 08Financial Position Analysis
Short Term Liabilities: SYRS has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: SYRS has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: SYRS has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: SYRS's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SYRS has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: SYRS has less than a year of cash runway if free cash flow continues to reduce at historical rates of 15.6% each year
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 16:14 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Syros Pharmaceuticals, Inc. is covered by 9 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Leah Rush Cann | Brookline Capital Markets |
| Andrew Fein | H.C. Wainwright & Co. |
| Jason Butler | JMP Securities |